Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$15.63M$15.63M+17.9% vs Q1 2020 Net Income-$4.17M-$4.17MN/M vs Q1 2020 EPS Diluted-$0.07-$0.07N/M vs Q1 2020 Operating Income-$5,059,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Free Cash Flowderived-$12,166,000N/M Margins · derivedOperating margin-32.4%−3.3 pt vs Q1 2020
Net margin-26.7%+0.4 pt vs Q1 2020
ended Mar 31, 2021 · filed May 17, 2021 · 47 d after period end